Development and clinical validation of a circulating tumor DNA test for the identification of clinically actionable mutations in nonsmall cell lung cancer

Publisher： John Wiley & Sons Inc

E-ISSN： 1098-2264|57|4|211-220

ISSN： 1045-2257

Source： GENES, CHROMOSOMES AND CANCER, Vol.57, Iss.4, 2018-04, pp. : 211-220

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Volumetric tumor growth in advanced non‐small cell lung cancer patients with EGFR mutations during EGFR‐tyrosine kinase inhibitor therapy

By  

CANCER, Vol. 119, Iss. 21, 2013-11 ,pp. : 3761-3768

John Wiley & Sons Inc

Access to resources Recommend Favorite

The impact of EGFR mutations on gefitinib sensitivity in non-small cell lung cancer

By Suzuki Takeshi   Mitsudomi Tetsuya   Hida Toyoaki  

Personalized Medicine, Vol. 1, Iss. 1, 2004-12 ,pp. : 27-34

Future Medicine

Access to resources Recommend Favorite

Clinical Characteristics of 274 Non-Small Cell Lung Cancer Patients in China

By  

Oncology Research and Treatment, Vol. 36, Iss. 5, 2013-04 ,pp. : 248-254

Karger

Access to resources Recommend Favorite

The Peptide Nucleic Acid-Locked Nucleic Acid Polymerase Chain Reaction Clamp-Based Test for Epidermal Growth Factor Receptor Mutations in Bronchoscopic Cytological Specimens of Non-Small Cell Lung Cancer

By  

Oncology, Vol. 82, Iss. 6, 2012-06 ,pp. : 341-346

Karger

Access to resources Recommend Favorite

Short report: Monitoring ESR1 mutations by circulating tumor DNA in aromatase inhibitor resistant metastatic breast cancer

By  

INTERNATIONAL JOURNAL OF CANCER, Vol. 137, Iss. 10, 2015-11 ,pp. : 2513-2519

John Wiley & Sons Inc

Access to resources Recommend Favorite